Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc (NASDAQ: MRN) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program.

Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years

Shares of Moderna Inc. MRNA, +11.03% shot up 9.3% in morning trading Monday, after Nasdaq said it was adding the drugmaker to the Nasdaq 100 Index NDX, +1.71% , before the market opens on July 20.

Moderna's stock shoots up as it is set to join the Nasdaq 100

Nasdaq

NEW YORK, July  13, 2020  (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Monday, July 20, 2020.  

Moderna, Inc. to Join the NASDAQ-100 Index Beginning July 20, 2020

Inovio Pharmaceuticals

Optimistic investors are bidding up shares of both companies, but which one is the better stock pick?

Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

Moderna's COVID-19 Vaccine And Other News: The Good, Bad And Ugly Of Biopharma

AstraZeneca

Johnson & Johnson

Pfizer

AstraZeneca, Johnson & Johnson, Merck, and Pfizer will also field questions from lawmakers.

Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21

This story has a long way to go before being over.

Coronavirus Vaccine Race: Moderna or Inovio?

After a solid run since starting at the sub-$20 levels at the start of the year, Moderna (NASDAQ:MRNA) continues to attract plenty of buying and selling activity. Ultimately, the direction of MRNA stock depends on the company’s developments in delivering a vaccine for the novel coronavirus.

Why Investors Should Take Another Look at Moderna’s Many Advantages

Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.

Moderna Collaborates to Support Coronavirus Vaccine Supply

Vaxart

Both companies are developing new types of vaccines. The risk is high -- but so is potential for share performance.

Coronavirus Vaccine Race: Moderna or Vaxart?

Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.

Moderna Completes Enrollment in Phase II Coronavirus Study

Novavax

The U.S. government has awarded biotech company Novavax $1.6 billion towards trials, commercialization, and manufacturing of its potential Covid-19 vaccine candidate NVX-CoV2373. [1] This marks the largest award yet under “Operation Warp Speed” a federal government program that intends to.

Is Novavax A Better Investment Than Moderna?

Moderna Inc (NASDAQ: MRNA) announced another manufacturing deal Thursday for mRNA-1273, its vaccine candidate for the novel coronavirus.

Moderna Strikes Another Coronavirus Vaccine Manufacturing Deal To Ensure Overseas Supply

Here's why an increasing number of short-sellers are betting against Moderna.

4 Reasons Investors Are Betting Against Moderna

Shares of Moderna Inc. MRNA, +0.80% gained 0.5% in premarket trading on Thursday after the drugmaker announced another manufacturing deal for its still investigational COVID-19 vaccine.

Moderna signs on for another COVID-19 vaccine manufacturing deal

Editas Medicine

Sangamo Therapeutics

These three stocks are positioned for growth -- but investors must tread carefully in the short term.

3 Top Biotech Stocks to Watch in July

Shares of potential COVID-19 developers have surged with each bit of news. But one offers better prospects for investors.

In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?

Sinovac Biotech

The World Health Organization this week said 21 candidate vaccines are in clinical trials at the moment, meaning they are being tested on human volunteers.

Pharma industry balancing accessibility and intellectual property rights in coronavirus vaccine race

Investors continue to wait for detailed phase 1 data for the coronavirus vaccine.

Moderna Completes Enrollment in Phase 2 COVID-19 Vaccine Study; Phase 3 Start on Track

It won't be a slam dunk for vaccines to turn the tide against the pandemic.

3 Reasons You Shouldn't Get Your Hopes Too High About COVID-19 Vaccines

Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”

Is There a Coronavirus Vaccine Yet?

The two sides are apparently arguing over several issues, including protocols and information sharing.

Report: Moderna and Feds Fight Over Coronavirus Vaccine Clinical Trials

BioNTech SE

iShares Nasdaq Biotechnology ETF

Regeneron Pharmaceuticals

Sanofi

COVID-19 has been the biggest driver of the stock market this year, whether it was the crash in March or recovery that has taken place since then.

5 Speculative COVID-19 Stocks That Could Still Surge

Dynavax Technologies

Gilead Sciences

Eli Lilly

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

Moderna (NASDAQ: MRNA) stock has declined by close to 10% over the last two trading days. There are a couple of developments that could be putting pressure on the stock.

News for Moderna Stock (MRNA)